IGC Pharma

Home
IGC Pharma

We are a clinical stage pharmaceutical company, formerly known as India Globalization Capital, Inc.

About IGC Pharma (dba IGC):

IGC Pharma is an AI-powered, clinical-stage biotechnology company focused on developing innovative treatments for Alzheimer's disease and transforming patient care with fast-acting, safe, and effective solutions. Our portfolio includes the TGR family, including TGR-63, which targets amyloid plaques, a hallmark of Alzheimer's. The IGC-C and IGC-M platforms are advancing

in preclinical studies, focusing on metabolic disorders, tau proteins, early plaque formation, and multiple disease hallmarks. Our lead therapeutic candidate, IGC-AD1, is a cannabinoid-based treatment currently in a Phase 2 trial for agitation in dementia associated with Alzheimer's (clinicaltrials.gov, NCT05543681). Clinical data for IGC-AD1 demonstrated that it has the potential to transform patient care by offering faster-acting and more effective relief compared to traditional medications. Additionally, our AI models are designed to predict potential biomarkers for the early detection of Alzheimer's, optimize clinical trials, and predict receptor affinity, among others. With 28 patent filings and a commitment to innovation, IGC Pharma is dedicated to advancing pharmaceutical treatments and improving the lives of those affected by Alzheimer's and related conditions.

24/07/2025

IGC Pharma will present 3 scientific posters at the Alzheimer’s Association International Conference 2025, highlighting our artificial intelligence achievements in Alzheimer’s research.

Our presentations explore how AI can support earlier detection, identify high-value clinical opportunities, and streamline drug discovery for underserved and low-resource populations.

Authored by our international research team:

• Poster 108629 – Néstor González, Paola Ruiz, Diego Rodríguez‑Soacha, Daniel Crovo, Ram Mukunda

• Poster 108625 – Paola Ruiz, Néstor González, Daniel Crovo, Catalina Ibañez, Pablo Arbeláez, Ram Mukunda

• Poster 108631 – Daniel Crovo, Paola Ruiz, Néstor González, Pablo Arbeláez, Ram Mukunda

We’re honored to contribute to the world’s largest dementia research forum and to continue advancing innovation in neurodegeneration.

22/07/2025

We’re proud to celebrate the outstanding achievement of Dr. Jagadeesh Rao. He was selected from over 360 nominations across 125 countries. With more than 15 years of contributions to neuroscience, psychiatry, and molecular biology, Dr. Rao continues to shape the future of neurodegenerative research.

His recent work on Alzheimer ’s-related agitation and epigenetic changes in the brain has played a key role in advancing IGC-AD1, IGC’s investigational drug currently in Phase 2 trials. This global recognition reinforces IGC Pharma’s commitment to pioneering science-backed therapeutics for Alzheimer’s disease.

Read more: https://igcpharma.com/igc-pharmas-principal-scientist-dr-jagadeesh-rao-receives-best-researcher-award-at-11th-annual-world-neuroscience-awards/

11/07/2025

A Breakthrough Moment from IGC Pharma: Powered by AI

We’re proud to introduce MINT-AD, our proprietary AI platform designed to identify individuals at high risk of Alzheimer’s years before symptoms appear. Built on multimodal data, including brain scans, genomics, and lifestyle, MINT-AD is designed for scale and personalized diagnostics to support earlier detection and precision care.

Read more: https://investor.igcpharma.com/igc-pharma-introduces-mint-ad-proprietary-ai-platform-to-predict-alzheimers-risk/

, , , , , , , ,

01/07/2025

IGC Pharma hosted its Fiscal Year-End 2025 Shareholder Update Call yesterday, covering key milestones from the past year and our outlook for the CALMA Trial, AI platform, and pipeline expansion.

Replay available here: https://www.webcaster4.com/Webcast/Page/2938/52547

, , , , , ,

30/06/2025

Save the date! IGC Pharma to Host Fiscal Year-End 2025 Shareholder Update Call on June 30 at 11:00 am ET. We invite investors and stakeholders to join us for a business update and live Q&A with management.

Read the full press release: https://investor.igcpharma.com/igc-pharma-fiscal-year-2025/

Dial-in or stream live: https://www.webcaster4.com/Webcast/Page/2938/52547

27/06/2025

📣 Join the IGC Pharma Webcast

We invite you to join our upcoming webcast, where we’ll provide updates on IGC Pharma’s latest clinical developments, research initiatives, and strategic priorities.

This is a valuable opportunity to hear directly from our leadership team about our progress in Alzheimer’s research and innovation in neurodegenerative disease treatment.

Focused on advancing care through clinical trials, AI-powered drug development, and patient-centered research.

Join the webcast
https://www.webcaster4.com/Webcast/Page/2938/52547

🗓 Date: Monday, June 30, 2025
🕚 Time: 11:00 A.M. Eastern Time
Replay available through: September 30, 2025

Dial-in numbers:
- US: (888) 506 0062
- International: (973) 528 0011
Access Code: 370284

Driving innovation in healthcare, together

26/06/2025

Meet Our Summer Navigators

We’re thrilled to welcome our incredible cohort of Summer Interns—students and graduates in Chemistry, Biology, and Pre-Pharmacy—who are bringing curiosity, dedication, and a passion for science to IGC Pharma this summer. 🔬

Over the past month, our Navigators have been actively involved in patient recruitment and have completed Good Clinical Practice (GCP) certification. Through this internship, they’re gaining exposure to clinical trials, drug development, and the research that drives progress in healthcare.

We’re proud to support this next generation of researchers as they continue their journey into science, medicine, and innovation. 🧪

Say hello to:
Timag Sherif
Meti Abdella
Kiersten N. Chaney
Alexander Antram
Shaimaa Hammett

Let’s build the future of healthcare, together.

24/06/2025

We’re proud to announce the expansion of our Phase 2 CALMA clinical trial evaluating IGC-AD1 for agitation in Alzheimer’s dementia, with a new site opening at Tekton Research in Yukon, Oklahoma. This strategic addition reflects IGC Pharma’s commitment to addressing regional healthcare disparities and enhancing diversity across our clinical studies.

Led by Dr. David McCoy, a board-certified neurologist and native Oklahoman, the Yukon site brings deep expertise in Alzheimer’s research and strengthens our ability to reach underrepresented populations.

This milestone also underscores our broader mission: to combine advanced clinical research with AI-powered innovation—to accelerate drug discovery, optimize clinical trials, and improve patient targeting in the fight against neurodegenerative diseases.

13/06/2025

IGC Pharma expands CALMA Phase II Alzheimer’s Trial to Include Renowned Butler Hospital's Memory and Aging Program

We’re proud to share that IGC Pharma has expanded its Phase 2 clinical trial, CALMA, to include the prestigious Butler Hospital's Memory and Aging Program, affiliated with the Warren Alpert Medical School of Brown University in Providence, Rhode Island.

The CALMA trial is evaluating IGC-AD1, our investigational therapy for agitation in Alzheimer’s disease, a condition that affects the majority of people living with Alzheimer’s and significantly impacts caregivers.

Butler Hospital's Memory and Aging Program is nationally recognized for its leadership in Alzheimer’s research. The program is committed to advancing care and improving outcomes for patients and families.

This collaboration marks an important milestone as we continue moving closer to delivering a potential new treatment for those affected by agitation in Alzheimer’s.

22/05/2025

We’re proud to share that IGC Pharma has a second site in for our Phase 2 study, evaluating IGC-AD1 for the of in .

With around 12.5% of Puerto Ricans over the age of 65 living with Alzheimer’s, a notably higher rate than in the continental U.S., this site addresses both a critical need and a meaningful opportunity to ensure broader representation in .

Our partnership with SCB Research, recognized for its outstanding from a perspective, allows us to engage directly with the community and gather essential data to help address the specific needs of .

Full info here: https://investor.igcpharma.com/igc-pharmas-puerto-rico-calma-trial-site/

21/05/2025

Join Us Live! with Ram Mukunda, CEO of IGC Pharma

We’re excited to invite you to a Fireside Chat with Ram Mukunda, CEO of IGC Pharma, during A.G.P./Alliance Global Partners Annual Virtual Healthcare Company Showcase.

• Date: May 21, 2025
• Time: 12:20 PM ET
• Location: Online (Zoom)

Don't miss this opportunity to hear directly from one of the leading voices in .

Register here: https://us02web.zoom.us/webinar/register/WN_jB1HgKLvQFmUfC6VBT11mw #/registration

13/05/2025

IGC Pharma presented new data at the 2025 Genetic Toxicology Association Meeting, highlighting findings from our GLP-compliant study on one of the in IGC-AD1, our investigational drug.

The study found no evidence of —an important requirement as we advance toward larger .

Presented in , this marks another step forward in our commitment to developing safe, effective for Alzheimer’s .

Learn more: https://investor.igcpharma.com/igc-pharma-presents-genetic-toxicology-safety-data-on-api-in-igc-ad1-at-the-2025-genetic-toxicology-association-meeting/

Address

Telephone

+13019830998

Website

https://igcpharma.com/

Alerts

Be the first to know and let us send you an email when IGC Pharma posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to IGC Pharma:

Shortcuts

Address
Telephone
Alerts
Contact The Practice
Claim ownership or report listing
Want your practice to be the top-listed Clinic?

Country:

City:

About IGC

IGC has two lines of business: infrastructure and h**p-derived medical cannabis/industrial h**p. The company is based in Maryland, U.S.A.